At AAVACC Pte Ltd we are focused on developing novel veterinary vaccines using ACM technology developed by our parent company, ACM Biolabs Pte Ltd. Artificial Cell Membrane (“ACM”) technology allows us to stabilize and deliver functional, folded viral and bacterial cell-surface antigens to induce a strong immune reaction. The safety of the platform technology has been demonstrated and efficacy via both injected and oral dosages using has been proven. We are currently scaling up and bringing our first vaccines through regulatory approvals, however we are open to licensing or co-development of vaccines with animal health partners.
The company was incorporated in Singapore in 2017.
Dr. Madhavan Nallani
Developed the core intellectual property of the company while working in Germany, the Netherlands and Singapore (at the Institute of Materials Research & Engineering and also at Nanyang Technological University).
Dr. Peter Moran
Previously co-founded Singular ID, a successful Singapore technology company which was acquired by one of the world’s largest pharmaceutical packaging companies.
Dr. Erich Erber
Founder the Erber Group, an Austrian animal nutrition company, which consists of more than 50 affiliates in all continents. Recipient of numerous awards including the Austrian Export award and Ernst & Young Entrepreneur of the Year and is an Honorary Senator of the University of Veterinary Medicine and the University of Natural Resources and Applied Life Sciences, Vienna.
Erich is the key investor representative on ACM Biolabs' Board of Directors.
Dr. Randolph Seidler
Previously lead the global R&D and Business Development teams at Boehringer Ingelheim Animal Health with a focus on innovation in vaccines and pharmaceuticals with teams in North America, Europe and Asia. Oversaw the licensing, development and regulatory approval of numerous successful vaccines in life stock and companion animals.
AAVACC Pte Ltd is majority owned by its parent company, ACM Biolabs Pte Ltd, the remaining equity of the company is held by strategic partners, such as San Pacific Investments Pte Ltd.